Literature DB >> 15897867

Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP.

Eriko Nitta1, Koji Izutsu, Yuko Yamaguchi, Yoichi Imai, Seishi Ogawa, Shigeru Chiba, Mineo Kurokawa, Hisamaru Hirai.   

Abstract

Evi-1 is a transcription factor that is implicated in leukemic transformation of hematopoietic cells. Two distinct alternative forms, Evi-1a and Evi-1c, are generated from the EVI-1 gene. Whereas Evi-1a is widely recognized as an oncoprotein, a role for Evi-1c, which has an additional PR domain in the amino-terminus of Evi-1a, in leukemogenesis, has not been elucidated thus far. Aberrant oligomerization of transcription factors has recently emerged as a prevalent mechanism for activating their oncogenic potential in hematopoietic malignancies. Here, to study the mechanisms that underlie Evi-1-mediated oncogenesis, we investigated formation of oligomeric complexes by the Evi-1 proteins. We show that Evi-1a forms homo-oligomers, whereas Evi-1c exclusively exists as a monomer in mammalian cells. Remarkably, Evi-1c has lost the ability to interact with CtBP, a transcriptional corepressor that associates with Evi-1a. As a consequence, the ability of Evi-1c to repress transforming growth factor-beta (TGF-beta) signaling is significantly abrogated. These results identify a novel function of a PR domain to regulate oligomerization of transcription factors and suggest that homo-oligomerization may play a critical role in corepressor recruitment by the Evi-1 proteins. In addition, we found that the chimeric oncoprotein acute myelocytic leukemia (AML)1-Evi-1, generated in t(3;21) leukemia, also forms homo-oligomers and hetero-oligomers with Evi-1a, while it did not interact with Evi-1c. Consistent with the results, repression of TGF-beta by AML1-Evi-1 was significantly enhanced by Evi-1a, whereas it was hardly affected by the presence of Evi-1c. These results suggest that oligomerization may contribute to the oncogenic potential of Evi-1-containing proteins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897867     DOI: 10.1038/sj.onc.1208754

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

1.  Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer.

Authors:  Xiyun Deng; Yanna Cao; Yan Liu; Fazhi Li; Kamalanathan Sambandam; Srinivasan Rajaraman; Archibald S Perkins; Alan P Fields; Mark R Hellmich; Courtney M Townsend; E Aubrey Thompson; Tien C Ko
Journal:  Mol Carcinog       Date:  2011-12-07       Impact factor: 4.784

Review 2.  Evi-1 as a critical regulator of leukemic cells.

Authors:  Susumu Goyama; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2010-06-08       Impact factor: 2.490

3.  Overexpression of PRDM16 in the presence and absence of the RUNX1/PRDM16 fusion gene in myeloid leukemias.

Authors:  Sawcène Hazourli; Pierre Chagnon; Martin Sauvageau; Raouf Fetni; Lambert Busque; Josée Hébert
Journal:  Genes Chromosomes Cancer       Date:  2006-11       Impact factor: 5.006

4.  Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta lytic switch protein functions as a tetramer.

Authors:  Wei Bu; Kyla Driscoll Carroll; Diana Palmeri; David M Lukac
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

5.  Direct interaction between the PRDM3 and PRDM16 tumor suppressors and the NuRD chromatin remodeling complex.

Authors:  Danton Ivanochko; Levon Halabelian; Elizabeth Henderson; Pavel Savitsky; Harshika Jain; Edyta Marcon; Shili Duan; Ashley Hutchinson; Alma Seitova; Dalia Barsyte-Lovejoy; Panagis Filippakopoulos; Jack Greenblatt; Evelyne Lima-Fernandes; Cheryl H Arrowsmith
Journal:  Nucleic Acids Res       Date:  2019-02-20       Impact factor: 16.971

6.  Lethal neonatal bone marrow failure syndrome with multiple congenital abnormalities, including limb defects, due to a constitutional deletion of 3' MECOM.

Authors:  Lars T van der Veken; Merel C Maiburg; Floris Groenendaal; Mariëlle E van Gijn; Andries C Bloem; Claudia Erpelinck; Stefan Gröschel; Mathijs A Sanders; Ruud Delwel; Marc B Bierings; Arjan Buijs
Journal:  Haematologica       Date:  2018-02-08       Impact factor: 9.941

7.  PR-domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cell function.

Authors:  Yi Zhang; Sandra Stehling-Sun; Kimberly Lezon-Geyda; Subhash C Juneja; Lucie Coillard; Gouri Chatterjee; Charles A Wuertzer; Fernando Camargo; Archibald S Perkins
Journal:  Blood       Date:  2011-06-10       Impact factor: 22.113

8.  Deletion of Mecom in mouse results in early-onset spinal deformity and osteopenia.

Authors:  Subhash C Juneja; Alin Vonica; Caroline Zeiss; Kimberly Lezon-Geyda; Bogdan Yatsula; David R Sell; Vincent M Monnier; Sharon Lin; Thomas Ardito; David Eyre; David Reynolds; Zhenqiang Yao; Hani A Awad; Hongbo Yu; Michael Wilson; Sylvie Honnons; Brendan F Boyce; Lianping Xing; Yi Zhang; Archibald S Perkins
Journal:  Bone       Date:  2013-12-04       Impact factor: 4.398

9.  Prdm16 is required for normal palatogenesis in mice.

Authors:  Bryan C Bjork; Annick Turbe-Doan; Mary Prysak; Bruce J Herron; David R Beier
Journal:  Hum Mol Genet       Date:  2009-12-11       Impact factor: 6.150

10.  Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes.

Authors:  Torsten A Konrad; Anna Karger; Hubert Hackl; Ilse Schwarzinger; Irene Herbacek; Rotraud Wieser
Journal:  J Leukoc Biol       Date:  2009-07-15       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.